[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638613":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":32,"locations":42,"responsibleParty":74,"collaborators":78,"id":80,"slug":22,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":89,"enrollmentInfo":90,"targetDuration":22,"studyType":93,"phases":94,"briefSummary":96,"conditions":97,"keywords":101,"overallStatus":110,"whyStopped":22,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":120},{"fullName":5,"class":6},"Hallym University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Semaglutide + BAT Evaluation","EXPERIMENTAL","Adults with obesity initiating semaglutide (0.25 mg → 2.4 mg over 20 weeks, maintained for 4 weeks; total 24 weeks). At baseline and 24 weeks, ¹⁸FDG-PET\u002FCT with individualized cold stimulation (water-circulating cooling vest at 16°C, 60 minutes) and liver MRI (PDFF + MRE) are performed.",[13,14,15],"Drug: Semaglutide (Wegovy®)","Procedure: ¹⁸FDG-PET\u002FCT with cold stimulation","Procedure: Liver MRI (PDFF + MRE)",[17,23,28],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Semaglutide (Wegovy®)","Once-weekly subcutaneous injection, titrated from 0.25 mg to 2.4 mg over 20 weeks per standard protocol. Standard of care treatment for obesity.",[9],null,{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":22},"PROCEDURE","¹⁸FDG-PET\u002FCT with cold stimulation","Whole-body ¹⁸FDG-PET\u002FCT (5.18 MBq\u002Fkg, max 370 MBq) after 60-minute individualized cold stimulation using a water-circulating cooling vest (Polar Products Arctic Chiller, starting 16°C). Performed at baseline (V1) and 24 weeks (V7). BAT activity quantified per BARCIST 1.0.",[9],{"type":24,"name":29,"description":30,"armGroupLabels":31,"otherNames":22},"Liver MRI (PDFF + MRE)","Hepatic proton density fat fraction (MRI-PDFF) and liver stiffness by MR elastography (MRE) using Siemens MAGNETOM Vida 3T. Performed at baseline (V1) and 24 weeks (V7).",[9],[33,38],{"name":34,"role":35,"phone":36,"phoneExt":22,"email":37},"Hun Jee Choe Hallym University Dongtan Sacred Heart Hospital, MD, PhD","CONTACT","+82-31-8086-2869","hunjeechoe@gmail.com",{"name":39,"role":35,"phone":40,"phoneExt":22,"email":41},"Hye Jeong Lee Hallym University Dongtan Sacred Heart Hospital, CRC","+82-10-4694-3886","geumzzogi@naver.com",[43,58],{"facility":44,"status":22,"city":45,"state":46,"zip":47,"country":48,"countryCode":22,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Hallym University Dongtan Sacred Heart Hospital","Hwaseong-si","Gyeonggi-do","18450","South Korea",{"type":50,"coordinates":51},"Point",[52,53],126.8169,37.20682,{"lat":53,"lon":52},[56],{"name":34,"role":35,"phone":57,"phoneExt":22,"email":37},"+82-10-9493-5703",{"facility":59,"status":22,"city":60,"state":46,"zip":61,"country":48,"countryCode":22,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Seoul National University Bundang Hospital","Seongnam-si","13620",{"type":50,"coordinates":63},[64,65],127.13778,37.43861,{"lat":65,"lon":64},[68,72],{"name":69,"role":35,"phone":70,"phoneExt":22,"email":71},"Soo Lim Seoul National University Bundang Hospital, MD, PhD","+82-10-9766-2706","limsoo@snu.ac.kr",{"name":69,"role":35,"phone":73,"phoneExt":22,"email":71},"+82-010-9766-2706",{"type":75,"investigatorFullName":76,"investigatorTitle":77,"investigatorAffiliation":44,"oldNameTitle":22,"oldOrganization":22},"PRINCIPAL_INVESTIGATOR","Hun Jee Choe","Assistant Professor, Division of Endocrinology and Metabolism",[79],{"name":44,"class":6},"100638613",false,"NCT07621640","Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study)","Brown Adipose Tissue as a Mechanistic Determinant of GLP-1 Receptor Agonist Treatment Response in Adults With Obesity: A Multicenter Prospective Cohort Study Using ¹⁸FDG-PET\u002FCT and Cold Stimulation Protocol","BAT-Sema","Inclusion Criteria:\n\n1. Age 20-70 years at the time of enrollment\n2. Initiating semaglutide (Wegovy) treatment for obesity (newly starting treatment)\n3. BMI ≥ 27 kg\u002Fm² with at least one weight-related comorbidity:\n\n   * Hypertension (SBP ≥130 or DBP ≥80 mmHg, or on antihypertensive medication)\n   * Dyslipidemia (LDL-C ≥130, TG ≥150, or low HDL-C, or on lipid-lowering medication)\n   * Non-alcoholic fatty liver disease (NAFLD\u002FMASLD, confirmed by imaging or ALT\u002FAST ≥1.5× ULN)\n   * Obstructive sleep apnea (AHI ≥5\u002Fhr or clinically diagnosed)\n   * Established cardiovascular disease (CAD, stroke, PAD)\n   * Obesity-related osteoarthritis of knee or hip with functional impairment OR BMI ≥ 30 kg\u002Fm² (regardless of comorbidity)\n4. Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 or type 2 diabetes mellitus\n2. History of neck surgery or radiation therapy to the neck\n3. Use of anti-obesity medications within 1 month prior to enrollment, or current use of beta-adrenergic blocking agents\n4. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2)\n5. Active malignancy, severe renal disease (eGFR \\\u003C30 mL\u002Fmin\u002F1.73m²), severe hepatic disease, or other severe endocrine disorders\n6. Pregnancy or breastfeeding\n7. Severe psychiatric illness or cognitive impairment precluding informed consent\n8. Contraindication to MRI (pacemaker, cochlear implant, non-MRI-compatible implants)\n9. Severe claustrophobia","ALL","20 Years","70 Years",{"count":91,"type":92},80,"ESTIMATED","INTERVENTIONAL",[95],"NA","This study investigates whether the activity of brown adipose tissue (BAT) - a special type of fat that burns energy as heat - can predict how well individuals with obesity respond to semaglutide (Wegovy), a once-weekly injectable weight loss medication. Participants who are starting semaglutide treatment will undergo ¹⁸FDG-PET\u002FCT imaging before and after 24 weeks of treatment. Prior to each PET\u002FCT scan, participants will wear a water-circulating cooling vest to activate BAT. By measuring BAT activity at baseline and comparing it with the degree of weight loss and metabolic improvement at 24 weeks, the investigators aim to identify BAT as a predictive biomarker for personalized obesity treatment.",[98,99,100],"Obesity","Metabolic Syndrome","Brown Adipose Tissue",[102,103,104,98,105,106,107,108,109],"Brown adipose tissue","Semaglutide","GLP-1 receptor agonist","FDG-PET\u002FCT","BAT","Biomarker","Weight loss","PDFF","NOT_YET_RECRUITING","2026-05-27",{"date":113,"type":114},"2026-06-02","ACTUAL",{"date":116,"type":92},"2026-06",{"date":118,"type":92},"2031-02",{"name":5,"class":6},2]